

## MEDI-CAL DRUG USE REVIEW (DUR) BOARD

## State of California DEPARTMENT OF HEALTH CARE SERVICES

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, May 20, 2014**, at the following location:

Department of Health Care Services 1500 Capitol Avenue Training Rooms B+C Sacramento, CA 95814

Medi-Cal Drug Use Review Board Meeting Agenda May 20, 2014 10:30 a.m. – 1 p.m.

Report Type*	Agenda It	tem	Presenter	Time
С	1. Welcome/Introduction		Pauline Chan, RPh, MBA	1030- 1045
Α	2. Call to Order/Review and Approval of Previous Minutes from February 18, 2014		Andrew Wong, MD	1045- 1050
	3. Old Business			
A	a. Review of Action Items from Previous Board Meeting:		Pauline Chan, RPh, MBA	1050-
	i.	Revisions to dashboard of relative drug costs for arthritis treatment drugs		1100
	ii.	Testing the AT alert for acetaminophen		
	iii.	Restrictions to promethazine with codeine cough syrup		
	iv.	Updates to CMS Annual Report Survey (question 3, answer b)		
	V.	Suggest CMS provide more guidance for calculation of cost- savings estimates		
	vi.	High Dose (HD) and Low Dose (LD) Alerts		
	vii.	Ingredient Duplication (ID) Alerts for HIV antiretroviral drugs		
	viii.	More in-depth look at the use of folic acid		
	ix.	Summarize potential DUR educational bulletin, alert, and review topics with each DUR Board Meeting packet		

	4. New Business		
R/A/D	a. Board Activities	DUR Board	1100-
	i. Cost Comparison of Selected Arthritis Medications		1110
	<b>b.</b> Pharmacy Update		
	i. Naloxone	Dorothy Uzoh, PharmD	1110- 1120
	ii. New CMS Annual Report Survey iii. New DUR Board Member Appointment	Pauline Chan, RPh, MBA	1120- 1130
R	c. Presentations: Prescription Opioid Overuse		
K	i. Pharmaceutical Supply Chain Thefts Reporting and Prevention	Virginia Harold, MS [Executive Director, California State Board of Pharmacy]	1130- 1150
	ii. Pharmacy Board Drug Abuse Subcommittee and Opioid Dispensing	Ramón Castellblanch, PhD [Board Member, California State Board of Pharmacy]	1150- 1210
R/A	<ul> <li>d. Quarterly Report – 1Q2014 (January – March 2014)</li> <li>e. Review of Physician Administered Drugs (PADs)</li> <li>f. Policy Impact Report: Tramadol</li> <li>g. Prospective DUR</li> <li>i. Review of DUR Alerts for New GCNs</li> <li>ii. Update: High Dose (HD) and Low Dose (LD) Alerts</li> </ul>	Amanda Fingado, MPH	1210- 1230
R/A/D	<ul> <li>h. Retrospective DUR</li> <li>i. Review of Retrospective DUR Criteria: Nicotine Replacement Therapy</li> <li>ii. Update: Folic Acid</li> <li>i. Review of DUR Publications</li> <li>i. DUR Educational Bulletin (March, 2014): Cough</li> <li>ii. DUR Educational Bulletin (May, 2014): ACE Inhibitors/ARBs, Diuretics, and Digoxin</li> <li>iii. Discussion/Recommendations for Future Bulletins</li> </ul>	Shalini Lynch, PharmD	1230- 1250
С	5. Public Comments		1250- 1255
	6. Consent Agenda		
I	a. Meeting feedback		
	<b>b.</b> Next meeting: September 16, 2014		
	10:30 a.m. – 1 p.m. DHCS Training Rooms B+C Sacramento, CA 95814		
	c. Proposed DUR Board Meeting Dates for 2015:		
	Tuesday, February 17, 2015 Tuesday, May 19, 2015 Tuesday, September 15, 2015 Tuesday, November 17, 2015		
	7. Adjournment		100

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu website (http://files.medi-cal.ca.gov/pubsdoco/dur/dur\_home.asp).

<sup>\*</sup> REPORT TYPE LEGEND: **A:** Action; **R:** Report; **I:** Information; **C:** Comment; **D:** Discussion
\*\* Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.